

B' Sub C3
CONT'D.

34. (New) A method for arresting the growth of or eradicating

tumors in a mammal bearing one or more tumors comprising the steps of:

administering a prolactin enhancer to said mammal;

contacting the cells of said tumor with a photosensitizer; and

exposing said contacted tumor cells to light.

35. (New) The method of claim 34 wherein said tumor bearing mammal is a human.

36. (New) The method of claim 35 wherein said prolactin enhancer is a member selected from the group consisting of prolactin, melatonin, metoclopramide, domperidone, 5-hydroxytryptophan, and pharmaceutically acceptable salts thereof.

37. (New) The method of claim 36 wherein said prolactin enhancer is melatonin or a pharmaceutically acceptable salt thereof.

Sub C3
38. (New) The method of claim 37 wherein said melatonin or a pharmaceutically acceptable salt thereof is administered in an amount within the range of about 0.5 to about 20 mg/person/day.

39. (New) The method of claim 36 wherein said prolactin enhancer is prolactin.

B⁺
concl'd.

40. (New) The method of claim 35 wherein said prolactin enhancer is administered at a time between about 19:00 and 1:00.

7PM - 1AM

41. (New) The method of claim 37 wherein said prolactin enhancer is administered at a time between about 19:00 and 1:00.

42. (New) The method of claim 38 wherein said melatonin or pharmaceutically acceptable salt thereof is administered at a time between about 19:00 and 1:00.

43. (New) The method of claim 35 wherein said photosensitizer is selected from the group consisting of porphyrin dyes, phthalocyanine dyes, cyanine dyes, benzophenoxazine analogs, and pharmaceutically acceptable salts thereof.

44. (New) The method of claim 37 wherein said photosensitizer is selected from the group consisting of porphyrin dyes, phthalocyanine dyes, cyanine dyes, benzophenoxazine analogs, and pharmaceutically acceptable salts thereof.

45. (New) The method of claim 38 wherein said photosensitizer is selected from the group consisting of porphyrin dyes, phthalocyanine dyes, cyanine dyes, benzophenoxazine analogs, and pharmaceutically acceptable salts thereof.

B1
concluded.

46. (New) The method of claim 40 wherein said photosensitizer is selected from the group consisting of porphyrin dyes, phthalocyanine dyes, cyanine dyes, benzophenoxazine analogs, and pharmaceutically acceptable salts thereof.

47. (New) The method of claim 41 wherein said photosensitizer is selected from the group consisting of porphyrin dyes, phthalocyanine dyes, cyanine dyes, benzophenoxazine analogs, and pharmaceutically acceptable salts thereof.

48. (New) The method of claim 43 wherein said photosensitizer is selected from the group consisting of porphyrin dyes, phthalocyanine dyes, cyanine dyes, benzophenoxazine analogs, and pharmaceutically acceptable salts thereof.

112 4th
on 43

49. (New) The method of claim 43 wherein said benzophenoxazine analog is a member selected from the group consisting of 5-ethylamino-9-diethylamino-2-iodobenzo[a]phenothiaziniumchloride and 5-ethylamino-9-diethylamino-benzo[a]phenothiazinium chloride.

50. (New) The method of claim 44 wherein said benzophenoxazine analog is a member selected from the group consisting of 5-ethylamino-9-diethylamino-2-iodobenzo[a]phenothiaziniumchloride and 5-ethylamino-9-diethylamino-benzo[a]phenothiazinium chloride.

B' CONCL'D.

51. (New) The method of claim 45 wherein said benzophenoxazine analog is a member selected from the group consisting of 5-ethylamino-9-diethylamino-2-iodobenzo[a]phenothiaziniumchloride and 5-ethylamino-9-diethylamino-benzo[a]phenothiazinium chloride.

52. (New) The method of claim 46 wherein said benzophenoxazine analog is a member selected from the group consisting of 5-ethylamino-9-diethylamino-2-iodobenzo[a]phenothiaziniumchloride and 5-ethylamino-9-diethylamino-benzo[a]phenothiazinium chloride.

53. (New) The method of claim 47 wherein said benzophenoxazine analog is a member selected from the group consisting of 5-ethylamino-9-diethylamino-2-iodobenzo[a]phenothiaziniumchloride and 5-ethylamino-9-diethylamino-benzo[a]phenothiazinium chloride.

54. (New) The method of claim 48 wherein said benzophenoxazine analog is a member selected from the group consisting of 5-ethylamino-9-diethylamino-2-iodobenzo[a]phenothiaziniumchloride and 5-ethylamino-9-diethylamino-benzo[a]phenothiazinium chloride.

55. (New) A therapeutic package for dispensing to, or for the use in dispensing to, a patient bearing one or more solid tumors comprising:

B' concub
one or more unit dosages of a photosensitizer and a finished pharmaceutical container therefor;

said container containing said unit dose or doses;

said container further containing or comprising labeling; and

said labeling directing the use of said package in the treatment of said tumor-bearing patient and further directing the use of said package in conjunction with the concomitant administration of one or more dosages of a prolactin enhancer.

56. (New) The package of claim 55 wherein said photosensitizer is selected from the group consisting of porphyrin dyes, phthalocyanine dyes, cyanine dyes, benzophenoxazine analogs, and pharmaceutically acceptable salts thereof.

57. (New) A therapeutic package for dispensing to, or for the use in dispensing to, a patient bearing one or more solid tumors comprising:

one or more unit dosages of a prolactin enhancer and a finished pharmaceutical container therefor;

said container containing said unit dose or doses;

said container further containing or comprising labeling; and

said labeling directing the use of said package in the treatment of said tumor-bearing patient and further directing the use of said package in conjunction with the concomitant administration of one or more dosages of a photosensitizer.